secwatch.observer — SEC 8-K summary
======================================

Issuer:     SAB Biotherapeutics, Inc. (SABS)
CIK:        0001833214
Form:       8-K
Filed at:   2024-09-09T23:59:59+00:00
Accession:  0000950170-24-104564
Event type: other_material
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SAB Bio completes Phase 1 healthy-volunteer enrollment; SAB-142 shows no serum sickness at 2.5 mg/kg
--------------------------------------------------------------------------------

- Phase 1 trial of SAB-142 for type 1 diabetes completed all planned healthy-volunteer cohorts; no serum sickness observed at target 2.5 mg/kg dose.
- Company now enrolling type 1 diabetes patients in the last cohort of the Phase 1 study.
- Topline Phase 1 data readout expected by end of 2024.
- SAB-142 is a first-in-class human anti-thymocyte immunoglobulin with differentiated safety profile compared to rabbit ATG.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024104564/0000950170-24-104564-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1833214/000095017024104564/sabs-20240909.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-104564

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer